How 4baseCare is Using Genomics & AI to Beat Cancer

The adoption of precision oncology is transforming cancer care across India by offering personalized treatment pathways for patients. Recently, the Bengaluru-based startup 4baseCare secured an additional Rs 38 crore top-up funding led by Infosys and growX Ventures. Consequently, this brings their total funding to Rs 128 crore to expand their diagnostic networks and scale their AI-led platform. Indeed, this capital will help the startup address critical diagnostic gaps in under-represented populations globally, a field covered in depth through our Oncology Speciality Courses.

Expanding Precision Oncology Globally

Currently, most genomic datasets and clinical trials heavily focus on Caucasian populations in the United States and Europe. However, cancer behaves differently across diverse populations, which creates treatment discrepancies for South Asian patients. Therefore, 4baseCare is developing solutions tailored to under-represented genetic groups across India, Latin America, and Southeast Asia. Additionally, the startup currently operates genomic laboratories in Dubai, Nepal, and the Philippines. They also plan to enter eight to ten new countries within the next year.

Decentralizing Genomic Diagnostics

Typically, Indian clinics must ship patient samples to centralized facilities in major metros like Bengaluru. This practice often delays critical diagnostic turnaround times for cancer patients in remote areas. Consequently, 4baseCare is partnering with leading healthcare institutions to build in-hospital laboratories. These partners include AIIMS Jammu, Max Healthcare, and Shankara Hospital. Because of these local labs, doctors can access genetic results much faster than before. As a result, clinical teams can initiate targeted therapy or immunotherapy without long delays.

Leveraging AI and Digital Twins

To assist oncologists, the startup developed its flagship platform called OncoTwin. Specifically, this technology integrates genomic, pathology, radiology, and clinical datasets to build digital replicas of patients. The platform then matches these profiles with real-world clinical outcomes from similar patients. However, the system does not directly prescribe or recommend therapies to clinicians. Instead, it provides actionable evidence to help medical teams make highly informed decisions. Ultimately, these digital insights will make advanced genomic profiling more affordable and widely accessible across emerging markets.

Frequently Asked Questions

Q1: What is OncoTwin and how does it assist oncologists?

OncoTwin is an AI platform that integrates clinical and genomic data to create digital patient replicas. Consequently, it matches these profiles with real-world outcomes to assist oncologists.

Q2: Why is decentralizing genomic testing important for cancer care in India?

Typically, shipping patient samples to centralized laboratories delays clinical decisions. As a result, local labs reduce turnaround times, which allows clinicians to begin therapies faster. For those looking to further their expertise in this field, we offer a Postgraduate Diploma In Medical Oncology.

References

1. Infosys-backed 4baseCare raises ₹128 cr, plans to take its cancer testingplatform global – ETHealthworld
2. Bengaluru startup 4baseCare raises ₹128cr to globalize precision cancer tech – NewsBytes
3. Infosys-backed precision oncology startup 4baseCare raises Rs 128 Cr – Entrackr

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.